Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad012 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Sheila M McSweeney und 4 weiteren Autor:innen. Beteiligte Einrichtung: St John's Institute of Dermatology, London, UK. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Urticaria. Die Arbeit nennt 1 Literaturangaben. Gefördert von: Medical Research Council, Medical Research Council Clinical Research Training Fellowship.
Abstract (Originalsprache)
Images of solar urticaria in which localized skin areas remained refractory to sun exposure following omalizumab injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- St John's Institute of Dermatology, London, UK.
- Department of Allergy, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Förderung
- Medical Research Council
- Medical Research Council Clinical Research Training Fellowship
Zitieren
APA
McSweeney, S. M., Bintcliffe, K., Fassihi, H., Sarkany, R., & Rutkowski, C. (2023). Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad012
Vancouver
McSweeney SM, Bintcliffe K, Fassihi H, Sarkany R, Rutkowski C. Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad012
BibTeX
@article{McSweeney2023,
author = {McSweeney, Sheila M and Bintcliffe, Keyna and Fassihi, Hiva and Sarkany, Robert and Rutkowski, Chris},
title = {Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad012}
}
EUVIMED